Impact of metabolic-associated fatty liver disease on the cholesterol efflux capacity of high-density lipoproteins in adolescents with type 2 diabetes.
José Antonio Orozco Morales, Aída Xochitl Medina Urrutia, Margarita Torres Tamayo, Juan Reyes Barrera, Esteban Jorge Galarza, Juan Gabriel Juárez Rojas, Pilar Dies Suarez, Nahum Méndez Sánchez, Luis Enrique Díaz Orozco, Lubia Velázquez-López, Patricia Medina Bravo
{"title":"Impact of metabolic-associated fatty liver disease on the cholesterol efflux capacity of high-density lipoproteins in adolescents with type 2 diabetes.","authors":"José Antonio Orozco Morales, Aída Xochitl Medina Urrutia, Margarita Torres Tamayo, Juan Reyes Barrera, Esteban Jorge Galarza, Juan Gabriel Juárez Rojas, Pilar Dies Suarez, Nahum Méndez Sánchez, Luis Enrique Díaz Orozco, Lubia Velázquez-López, Patricia Medina Bravo","doi":"10.3389/fped.2024.1462406","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Type 2 diabetes (DM2) is an emerging disease in the pediatric population. DM2 is associated with metabolic-associated fatty liver disease (MAFLD). High-density lipoproteins (HDLs) are lipoproteins that are believed to have atheroprotective properties that reduce the risk of cardiovascular disease (CVD). Current evidence suggests that the physicochemical and functional features of HDLs may play a key role in the pathogenesis of atherosclerosis.</p><p><strong>Objective: </strong>We aimed to assess the impact of MAFLD on cholesterol efflux capacity (CEC) in adolescents with DM2.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Setting: </strong>Attention clinic for Children with Diabetes of the Hospital Infantil de México Federico Gómez.</p><p><strong>Patients or other participants: </strong>This study included a total of 70 adolescents, 47 of which had DM2 and 23 were healthy individuals.</p><p><strong>Interventions: </strong>The presence of MAFLD was determined by MR spectroscopy with proton density fat fraction. We compared the distribution of HDL subtypes (HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c) and the chemical composition of HDLs (total protein, triglycerides, phospholipids, cholesteryl esters, and free cholesterol). HDL functionality was determined by the CEC, measuring the fluorescent cholesterol efflux from J774 macrophage cells.</p><p><strong>Main outcome measures: </strong>We were expecting to observe a decrease in HDL efflux capacity in adolescents with type 2 diabetes and MAFLD.</p><p><strong>Results: </strong>In our study, we observed a prevalence of MAFLD in 66% of adolescents with DM2, similar to that reported in other international studies (60%-80%). In the population with DM2 and MAFLD, we did not observe a decrease in CEC. Initially we found a slight elevation of CEC in adolescents with DM2, however, with the increase in liver fat, a little decrease is observed, which could explain a probable metabolic phenomenon, since the physicochemical composition and distribution of the particles is associated with the percentage of liver fat. A positive correlation between the percentage of liver fat and the concentration of HDL2b (<i>p</i> = 0.011), HDL2a (<i>p</i> = 0.014) and average particle size (<i>p</i> = 0.011) and the proportion of triglycerides inside the particles (<i>p</i> = 0.007). Likewise, negative correlation were found with the percentage of liver fat, cholesterol esters (<i>p</i> = 0.010) and free cholesterol of the particles (<i>p</i> < 0.001). We observed a positive correlation between CEC and the percentage of triglycerides (<i>p</i> = 0.007), and a negative correlation with the percentage of cholesterol esters (<i>p</i> = 0.05) inside the HDL's particles.</p><p><strong>Conclusions: </strong>In this group of adolescents with DM2, the presence of MAFLD was not associated with CEC; however, it is associated with abnormalities in the distribution and lipid composition of HDL particles. The momentum generated by the original proposal for MAFLD in the adult population and following the recommendations for pediatric MAFLD will be a step forward in helping to study the impact of MAFLD on the atheroprotective properties of HDL in the pediatric population.</p>","PeriodicalId":12637,"journal":{"name":"Frontiers in Pediatrics","volume":"12 ","pages":"1462406"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703661/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fped.2024.1462406","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Type 2 diabetes (DM2) is an emerging disease in the pediatric population. DM2 is associated with metabolic-associated fatty liver disease (MAFLD). High-density lipoproteins (HDLs) are lipoproteins that are believed to have atheroprotective properties that reduce the risk of cardiovascular disease (CVD). Current evidence suggests that the physicochemical and functional features of HDLs may play a key role in the pathogenesis of atherosclerosis.
Objective: We aimed to assess the impact of MAFLD on cholesterol efflux capacity (CEC) in adolescents with DM2.
Design: A cross-sectional study.
Setting: Attention clinic for Children with Diabetes of the Hospital Infantil de México Federico Gómez.
Patients or other participants: This study included a total of 70 adolescents, 47 of which had DM2 and 23 were healthy individuals.
Interventions: The presence of MAFLD was determined by MR spectroscopy with proton density fat fraction. We compared the distribution of HDL subtypes (HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c) and the chemical composition of HDLs (total protein, triglycerides, phospholipids, cholesteryl esters, and free cholesterol). HDL functionality was determined by the CEC, measuring the fluorescent cholesterol efflux from J774 macrophage cells.
Main outcome measures: We were expecting to observe a decrease in HDL efflux capacity in adolescents with type 2 diabetes and MAFLD.
Results: In our study, we observed a prevalence of MAFLD in 66% of adolescents with DM2, similar to that reported in other international studies (60%-80%). In the population with DM2 and MAFLD, we did not observe a decrease in CEC. Initially we found a slight elevation of CEC in adolescents with DM2, however, with the increase in liver fat, a little decrease is observed, which could explain a probable metabolic phenomenon, since the physicochemical composition and distribution of the particles is associated with the percentage of liver fat. A positive correlation between the percentage of liver fat and the concentration of HDL2b (p = 0.011), HDL2a (p = 0.014) and average particle size (p = 0.011) and the proportion of triglycerides inside the particles (p = 0.007). Likewise, negative correlation were found with the percentage of liver fat, cholesterol esters (p = 0.010) and free cholesterol of the particles (p < 0.001). We observed a positive correlation between CEC and the percentage of triglycerides (p = 0.007), and a negative correlation with the percentage of cholesterol esters (p = 0.05) inside the HDL's particles.
Conclusions: In this group of adolescents with DM2, the presence of MAFLD was not associated with CEC; however, it is associated with abnormalities in the distribution and lipid composition of HDL particles. The momentum generated by the original proposal for MAFLD in the adult population and following the recommendations for pediatric MAFLD will be a step forward in helping to study the impact of MAFLD on the atheroprotective properties of HDL in the pediatric population.
期刊介绍:
Frontiers in Pediatrics (Impact Factor 2.33) publishes rigorously peer-reviewed research broadly across the field, from basic to clinical research that meets ongoing challenges in pediatric patient care and child health. Field Chief Editors Arjan Te Pas at Leiden University and Michael L. Moritz at the Children''s Hospital of Pittsburgh are supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Pediatrics also features Research Topics, Frontiers special theme-focused issues managed by Guest Associate Editors, addressing important areas in pediatrics. In this fashion, Frontiers serves as an outlet to publish the broadest aspects of pediatrics in both basic and clinical research, including high-quality reviews, case reports, editorials and commentaries related to all aspects of pediatrics.